Understanding Pneumococcal Carriage and Disease

Pneumonia Clinical Trial

Official title:

Cross-sectional Study to Establish the Point Prevalence of Serotype 19A Pneumococcal Nasopharyngeal Carriage of Fully Vaccinated Children Aged 13-48 Months Following Introduction of PCV13.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01996007
• Other study ID #: OVG 2013/05
• Status: Completed
• Start date: March 2014
• Est. completion date: August 2015

Study information

• Verified date: November 2015
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Pneumococcus is a bacteria that causes disease of the respiratory tract (pneumonia and middle ear infections), blood poisoning, and meningitis. It is frequently carried by people in back of the throat without symptoms. Pneumococcal carriage in the Thames Valley region has been studied over the last 12 years with carriage rates having been shown to be reflective of disease potential and hence vaccine effect. During this time pneumococcal vaccines have been introduced into the routine immunisation schedules of this community. The PCV7 (A vaccine against 7 types of pneumococcus) vaccine has subsequently been noted to have had a significant impact in reducing vaccine serotype carriage and disease. Herd protection (indirect protection of unvaccinated individuals) has also been implicated with vaccine serotypes not being carried in parents of vaccinated children. The most common serotype carried since the introduction of PCV7 is 19A, which is included in the PCV13 vaccine (A vaccine against 13 types of pneumococcus). PCV13 has superseded PCV7 in the routine immunisation schedule, however its impact on carriage and disease in this community is yet to be evaluated.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1200
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 6 Months and older

Eligibility

Inclusion Criteria:

Children

• Parent/guardian of participant is willing and able to give informed consent for participation in the study.

• In good health as determined by a brief medical history and/or clinical judgement of the investigator

• Have received three doses of PCV13 as per infant immunisation schedule (as confirmed by red book or through vaccination history and age). Vaccination history will be confirmed by the child's GP or CHCD. The visit and sampling may still proceed if the vaccination history has not been confirmed beforehand and the participant subsequently excluded if they are found to not have received all three doses of PCV13.Aged 6-48 months and at least 28 days since their third PCV13 vaccination.

• Able (in the Investigators opinion) and willing to comply with all study requirements.

Parents/ Legal guardians

• Participant is willing and able to give informed consent for participation in the study.

• Is the child's legal guardian and lives in the same household with the child participating in the same study.

• In good health as determined by clinical judgement of the research staff

• Able (in the investigators opinion) and willing to comply with all study requirements.

Exclusion Criteria:

The participant may not enter the study if ANY of the following apply:

Children

• Parent/legal guardian unwilling or unable to give written informed consent to participate in the study.

• Parent/legal guardian less than 18 years of age at time of enrolment.

• Parent/legal guardian is listed on the study delegation log.

• Children who are unimmunised or have an incomplete course of PCV13.

• Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

• Febrile illness or temperature of 38°C on the day of the visit or in the preceding 24 hours.

• Respiratory illness on the day of the study visit or in the preceding 24 hours. A respiratory illness will be classified as a combination of at least two of the following symptoms: cough, sore throat, and runny nose.

• Administration of antibiotics in the month prior to sampling.

• A risk of nose bleed, including; a recent (within the last 24 hours) nose bleed, history of a bleeding disorder, history of severe nose bleeds or recent (within the last 3 months) nasal/craniofacial surgery.

• Receipt of blood products and/or plasma derivatives or any parenteral immunoglobulin preparation within 90 days.

Parents/ Legal guardians

• Participants who are unwilling or unable to give written informed consent to participate in the study.

• Less than 18 years of age at time of enrolment

• Is listed on the study delegation log

• Previous immunisation with pneumococcal conjugate vaccine.

• Participants who in the opinion of the investigator are unable to comply with study procedures or may be put at risk by participation in the study.

• Febrile illness or temperature of 38°C on the day of the visit or in the preceding 24 hours.

• Respiratory illness on the day of the study visit or in the preceding 24 hours. A respiratory illness will be classified as a combination of at least two of the following symptoms: cough, sore throat, and runny nose.

• Administration of antibiotics in the month prior to sampling.

• A risk of nose bleed, including; a recent (within the last 24 hours) nose bleed, history of a bleeding disorder, a history of severe nose bleeds or recent (within the last 3 months) nasal/craniofacial surgery.

• Receipt of blood products and/or plasma derivatives or any parenteral immunoglobulin preparation within 90 days.

Related Conditions & MeSH terms

• Meningitis
• Pneumonia
• Sepsis
• Septicaemia

Locations

Country	Name	City	State
United Kingdom	Oxford Vaccine Group	Oxford	Oxfordshire

Sponsors (2)

Lead Sponsor	Collaborator
University of Oxford	Pfizer

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Kandasamy R, Voysey M, Collins S, Berbers G, Robinson H, Noel I, Hughes H, Ndimah S, Gould K, Fry N, Sheppard C, Ladhani S, Snape MD, Hinds J, Pollard AJ. Persistent circulation of vaccine serotypes and serotype replacement after five years of UK infant i — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The presence of serotype 19A pneumococci on children's swabs		2 years
Secondary	The presence of pneumococcal serotypes on children's swabs		2 years
Secondary	The presence of pneumococcal serotypes on parents/legal guardians swabs		2 years
Secondary	The molecular sequence type of nasopharyngeal carriage isolates from children and parents/legal guardians.		2 years
Secondary	The serotype-specific and genotype-specific invasive disease potential of isolates recovered from children.		2 years
Secondary	The serotype specific pneumococcal antibodies levels in children and their parents/legal guardians		2 years